Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer
Abstract
Women with hereditary breast cancer are at high risk for contralateral breast cancer (CBC). To evaluate factors influencing CBC risk in women with BRCA mutations the funded study was designed to assess the impact of tamoxifen and radiotherapy on CBC. Records from a total of 874 Ashkenazi women with breast cancer diagnosed between 1990 and 1996 were reviewed to expand the initial cohort of 305 women treated between 1980 and 1990. Changes in medical record storage and HlPAA privacy regulations prevented the gathering of required basic clinical and/or follow-up information for an unacceptably large proportion of subjects. Because of the significant loss of patients to follow-up and lack of pathology material for genotyping alternative methods of attaining the study goals were sought. Specifically concatenation of the original 1980-1990 data-set with a similar ascertainment from another institution was performed and suggested a 53% contralateral risk reduction with adjuvant tamoxifen. A further 103 patients undergoing breast-conserving treatment were analyzed. This clinical ascertainment did not clearly support a benefit from tamoxifen (HR 0.71, 95% C.I. 0.23-2.2). However an expansion of the clinical ascertainment did suggest a benefit from tamoxifen (HR 0.37, 95% C.I 0.35) and no negative effect from radiation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2005
- Accession Number
- ADA479367
Entities
People
- Mark E. Robson
Organizations
- Memorial Sloan Kettering Cancer Center